Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.

U.S. healthcare is in the throes of an affordability crisis. The good news is that healthcare leaders have all the evidence, tools and expertise needed to keep the predicament from becoming a plight. Can they marshal the will to wield those weapons toward that end? 

The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.